About NeoCura
NeoCura is a Healthcare company based in Changping (China) founded in 2017 by Wang Yi. AI-enabled platforms for tumor diagnosis and immunotherapy are developed. NeoCura has raised $38.19 million across 2 funding rounds from investors including CDH, PICC Capital Investment Management and Jiayin Fund. Its chief executive, as recorded, is Wang Yi. Its focus areas include Life Sciences, Oncology, Medical Devices and Imaging.
Company details
NeoCura was founded in 2017 in Changping, China, within the biotechnology sector. Operations focus on AI-integrated platforms that analyze molecular and clinical data for cancer diagnostics and precision medicine. Key offerings include NeoCura for blood-based cancer detection, NeoCura Vac for neoantigen therapeutics guided by AI, and NeoCura Info for multi-omics bioinformatics services. These tools support tumor identification and treatment strategies.
- Headquarters Changping, China
- Founders Wang Yi
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website neocura.net
- Social LinkedIn
- Total Equity Funding$38.19M (USD)
in 2 rounds
- InvestorsCDH
& 6 more
Funding Insights of NeoCura
NeoCura has successfully raised a total of $38.19M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $38.19M
- Total Rounds 2
- First Round $38.19M
(Dec 2020)
- Investors Count 7
All 2 funding rounds of NeoCura with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | Series A | – | CDH, PICC Capital Investment Management | ||
| Dec 2020 | $38.19M | Series A | – | – |
7 investors in total: 6 institutional and 1 angel.
Investors in NeoCura
NeoCura has secured backing from 7 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include CDH, PICC Capital Investment Management and Jiayin Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and private debt firm focused on multiple sectors | cdhfund.com | Kowloon, China | ||
Venture capital firm | idgcapital.com | New York, United States | ||
Alwin Capital is focused on life sciences investment opportunities. | 2015 | alwincapital.com | Beijing, China | |
Investments in technology companies are managed by Kunlun Capital. | kunlun-cap.com | Beijing, China | ||
Manages diversified investment funds and portfolios for clients. | 2018 | picccim.com.cn | Xicheng, China | |
ZY Zhou Yahui | unknown_1e90770ba089431a8 |
Investor details for NeoCura
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NeoCura
1 people are tracked at NeoCura (1 in leadership).
| Name | Role | Group |
|---|---|---|
Wang Yi | Co-Founder & CEO | Leadership |
Complete people profiles for NeoCura
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NeoCura
3 dated milestones of NeoCura across 4 years, from founding to its latest funding, stage changes and deals.
- Founded NeoCura is founded.
- Funding First funding round of $38.2M.
- Funding Latest funding round, Series A,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neocura
Complete news archive for NeoCura
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeoCura
NeoCura was founded in 2017 and raised its 1st funding round 3 years after it was founded.
NeoCura is headquartered in Changping, China. It is registered at Changping, Beijing, China.
Wang Yi is the CEO of NeoCura, as recorded in our data. They have also founded this company.
NeoCura is a funded company, having raised a total of $38.19M across 2 funding rounds to date. The company's 1st funding round was a Series A of $38.19M, raised on Dec 2020.
NeoCura was founded in 2017 in Changping, China, within the biotechnology sector. Operations focus on AI-integrated platforms that analyze molecular and clinical data for cancer diagnostics and precision medicine. Key offerings include NeoCura for blood-based cancer detection, NeoCura Vac for neoantigen therapeutics guided by AI, and NeoCura Info for multi-omics bioinformatics services. These tools support tumor identification and treatment strategies.
NeoCura has 7 investors. Key investors include CDH, PICC Capital Investment Management, Jiayin Fund, Zhou Yahui, and IDG Capital.